Search NASA⌕ Search

SEARCH · Search NASA

Results for “Laboratory analysis”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 records
All sourcesNASA NTRSDOE OSTI
NASA NTRS2016

Exploration Laboratory Analysis

The Exploration Laboratory Analysis (ELA) project supports the Exploration Medical Capability (ExMC) risk to minimize or reduce the risk of adverse health outcomes and decrements in performance due to in-flight medical capabilities on human exploration missions. To mitigate this risk, the availability of inflight laboratory analysis instrumentation has been identified as an essential capability for manned exploration missions. Since a single, compact space-ready laboratory analysis capability to perform all exploration clinical measurements is not commercially available, the ELA project objective is to demonstrate the feasibility of emerging operational and analytical capability as a biomedical diagnostics precursor to long duration manned exploration missions. The initial step towards ground and flight demonstrations in fiscal year (FY) 2015 was the down selection of platform technologies for demonstrations in the space environment. The technologies selected included two Small Business Innovation Research (SBIR) performers: DNA Medicine Institutes rHEALTH X and Intelligent Optical Systems later flow assays combined with Holomics smartphone analyzer. The selection of these technologies were based on their compact size, breadth of analytical capability and favorable ability to process fluids in a space environment, among several factors. These two technologies will be advanced to meet ground and flight demonstration success criteria and requirements that will be finalized in FY16. Also, the down selected performers will continue the technology development phase towards meeting prototype deliverables in either late 2016 or 2017.

Laboratory analysis↗
NASA NTRS2016

Exploration Laboratory Analysis

The Exploration Laboratory Analysis (ELA) project supports the Exploration Medical Capability (ExMC) risk to minimize or reduce the risk of adverse health outcomes and decrements in performance due to in-flight medical capabilities on human exploration missions. To mitigate this risk, the availability of inflight laboratory analysis instrumentation has been identified as an essential capability for manned exploration missions. Since a single, compact space-ready laboratory analysis capability to perform all exploration clinical measurements is not commercially available, the ELA project objective is to demonstrate the feasibility of emerging operational and analytical capability as a biomedical diagnostics precursor to long duration manned exploration missions. The initial step towards ground and flight demonstrations in fiscal year (FY) 2015 was the downselection of platform technologies for demonstrations in the space environment. The technologies selected included two Small Business Innovation Research (SBIR) performers: DNA Medicine Institute's rHEALTH X and Intelligent Optical System's lateral flow assays combined with Holomic's smartphone analyzer. The selection of these technologies were based on their compact size, breadth of analytical capability and favorable ability to process fluids in a space environment, among several factors. These two technologies will be advanced to meet ground and flight demonstration success criteria and requirements. The technology demonstrations and metrics for success will be finalized in FY16. Also, the downselected performers will continue the technology development phase towards meeting prototype deliverables in either late 2016 or 2017.

In-Flight laboratory↗
NASA NTRS2013

Exploration Laboratory Analysis FY13

The Exploration Laboratory Analysis (ELA) project supports the Exploration Medical Capability (ExMC) risk, which is stated as the Risk of Inability to Adequately Treat an Ill or Injured Crew Member, and ExMC Gap 4.05: Lack of minimally invasive in-flight laboratory capabilities with limited consumables required for diagnosing identified Exploration Medical Conditions. To mitigate this risk, the availability of inflight laboratory analysis instrumentation has been identified as an essential capability in future exploration missions. Mission architecture poses constraints on equipment and procedures that will be available to treat evidence-based medical conditions according to the Space Medicine Exploration Medical Conditions List (SMEMCL), and to perform human research studies on the International Space Station (ISS) that are supported by the Human Health and Countermeasures (HHC) element. Since there are significant similarities in the research and medical operational requirements, ELA hardware development has emerged as a joint effort between ExMC and HHC. In 2012, four significant accomplishments were achieved towards the development of exploration laboratory analysis for medical diagnostics. These achievements included (i) the development of high priority analytes for research and medical operations, (ii) the development of Level 1 functional requirements and concept of operations documentation, (iii) the selection and head-to-head competition of in-flight laboratory analysis instrumentation, and (iv) the phase one completion of the Small Business Innovation Research (SBIR) projects under the topic Smart Phone Driven Blood-Based Diagnostics. To utilize resources efficiently, the associated documentation and advanced technologies were integrated into a single ELA plan that encompasses ExMC and HHC development efforts. The requirements and high priority analytes was used in the selection of the four in-flight laboratory analysis performers. Based upon the competition results, a down select process will be performed in the upcoming year. Looking ahead, this unified effort has positioned each element for an in-flight lab analysis demonstration of select diagnostics measurements in the 2015 timeframe.

Krihak, Michael↗
NASA NTRS1976

Gait Analysis Laboratory

Complete motion analysis laboratory has evolved out of analyzing walking patterns of crippled children at Stanford Children's Hospital. Data is collected by placing tiny electrical sensors over muscle groups of child's legs and inserting step-sensing switches in soles of shoes. Miniature radio transmitters send signals to receiver for continuous recording of abnormal walking pattern. Engineers are working to apply space electronics miniaturization techniques to reduce size and weight of telemetry system further as well as striving to increase signal bandwidth so analysis can be performed faster and more accurately using a mini-computer.

Source record↗
NASA NTRS2012

Exploration Laboratory Analysis - ARC

The Exploration Laboratory Analysis (ELA) project supports the Exploration Medical Capability (ExMC) risk, Risk of Inability to Adequately Treat an Ill or Injured Crew Member, and ExMC Gap 4.05: Lack of minimally invasive in-flight laboratory capabilities with limited consumables required for diagnosing identified Exploration Medical Conditions. To mitigate this risk, the availability of inflight laboratory analysis instrumentation has been identified as an essential capability in future exploration missions. Mission architecture poses constraints on equipment and procedures that will be available to treat evidence-based medical conditions according to the Space Medicine Exploration Medical Conditions List (SMEMCL). The SMEMCL provided diagnosis and treatment for the evidence-based medical conditions and hence, a basis for developing ELA functional requirements.

Krihak, Michael K.↗
NASA NTRS2014

NASA Laboratory Analysis for Manned Exploration Missions

The Exploration Laboratory Analysis (ELA) project supports the Exploration Medical Capability Element under the NASA Human Research Program. ELA instrumentation is identified as an essential capability for future exploration missions to diagnose and treat evidence-based medical conditions. However, mission architecture limits the medical equipment, consumables, and procedures that will be available to treat medical conditions during human exploration missions. Allocated resources such as mass, power, volume, and crew time must be used efficiently to optimize the delivery of in-flight medical care. Although commercial instruments can provide the blood and urine based measurements required for exploration missions, these commercial-off-the-shelf devices are prohibitive for deployment in the space environment. The objective of the ELA project is to close the technology gap of current minimally invasive laboratory capabilities and analytical measurements in a manner that the mission architecture constraints impose on exploration missions. Besides micro gravity and radiation tolerances, other principal issues that generally fail to meet NASA requirements include excessive mass, volume, power and consumables, and nominal reagent shelf-life. Though manned exploration missions will not occur for nearly a decade, NASA has already taken strides towards meeting the development of ELA medical diagnostics by developing mission requirements and concepts of operations that are coupled with strategic investments and partnerships towards meeting these challenges. This paper focuses on the remote environment, its challenges, biomedical diagnostics requirements and candidate technologies that may lead to successful blood/urine chemistry and biomolecular measurements in future space exploration missions. SUMMARY The NASA Exploration Laboratory Analysis project seeks to develop capability to diagnose anticipated space exploration medical conditions on future manned missions. To achieve this goal, NASA will leverage existing point-of-care technology to provide clinical laboratory measurements in space. This approach will place the project on a path to minimize sample, reagent consumption, mass, volume and power. For successful use in the space environment, NASA specific conditions such as micro gravity and radiation, for example, will also need to be addressed.

Exploration Medical Capability↗
DOE OSTI2018

FRMAC Laboratory Analysis RadResponder Gap Analysis and Web Portal Enhancements

The Federal Radiological Monitoring and Assessment Center (FRMAC) relies on accurate and defensible analytical laboratory data to support its mission. FRMAC Laboratory Analysis personnel are responsible for (1) receiving samples, (2) managing samples, and (3) providing data quality assurance. Currently, the RadResponder software application does not meet all these needs. With some modifications, RadResponder could meet the needs for sample receiving functions, but it does not meet the needs of sample management and data quality assurance functions. The FRMAC Laboratory Analysis team has discussed and reviewed the following options moving forward: Option 1: Make minor revisions to RadResponder to improve sample receiving capability, purchase and configure a commercial laboratory information management system (LIMS) to perform sample management and data quality assurance, and build an interface between RadResponder and the commercial-off-the-shelf LIMS. Option 2: Make major revisions to RadResponder for all FRMAC Laboratory Analysis functions to support required sample management and data quality assurance activities. Option 3: Create a custom-built LIMS system to interface with RadResponder. Note: All three options will require the development of a Laboratory Analysis web portal and will require funding for ongoing maintenance and training. The FRMAC Laboratory Analysis team highly recommends Option 1 as the best and most efficient path forward. Commercial-off-the-shelf LIMS products have been proven successful in the laboratory community for decades. Option 1 leverages these proven technologies and takes advantage of RadResponder's current strengths.

61 RADIATION PROTECTION AND DOSIMETRY↗
DOE OSTI2018

Summary of Observations from the 2017 Federal Radiological Monitoring and Assessment Center (FRMAC) Laboratory Analysis Training and Capstone Event

On August 15th thru 17th, 2017 the Federal Radiological Monitoring and Assessment Center (FRMAC) Laboratory Analysis division, the FRMAC Fly Away Laboratory (FAL), the FRMAC Assessment division, and the Mobile Environmental Response Laboratory (MERL) held a training and capstone event for staff from the Environmental Protection Agency (EPA), Remote Sensing Laboratory (RSL), Lawrence Livermore National Laboratory (LLNL), and Sandia National Laboratories (SNL). LAB-100, "Sample Control Training", LAB-200 "QA Specialist Training", and LAB-300 "Laboratory Analysis Manager Training" was given the first two days of the event. The purpose of the training and capstone event was to meet training requirements for billeted FRMAC Lab Analysis staff from RSL, LLNL, and SNL as well as raise awareness of the FRMAC Lab Analysis process with EPA staff as part of a Federal Emergency Management Agency — Nuclear Incident Response Team (FEMA-NIRT) laboratory standardization project. An objective of the standardization project was to help improve the transition of operations from DOE to EPA during a response. To do this effectively, detailed knowledge of the FRMAC Lab Analysis process by the EPA is needed. This training provided a good opportunity for this knowledge transfer. A capstone was held after the two-day training event to allow participants to practice the skills they learned in a realistic scenario. A scenario that was previously developed for a quarterly Consequence Management drill (i.e. Dark Phoenix) was used as the basis for the capstone, with laboratory analysis focused injects used to drive the exercise play. Each position within the FRMAC Lab Analysis Division exercised to specific objectives and helped to uncover gaps in the established processes. The lessons learned during this capstone are broken out in the following categories: Sample Control, In-Situ Gamma Spectroscopy, Analysis Request Forms (ARF), Shipping, QA/QC, Fly Away Laboratory (FAL), and Management.

54 ENVIRONMENTAL SCIENCES↗
NASA NTRS2014

NASA Laboratory Analysis for Manned Exploration Missions

The Exploration Laboratory Analysis (ELA) project supports the Exploration Medical Capability Element under the NASA Human Research Program. ELA instrumentation is identified as an essential capability for future exploration missions to diagnose and treat evidence-based medical conditions. However, mission architecture limits the medical equipment, consumables, and procedures that will be available to treat medical conditions during human exploration missions. Allocated resources such as mass, power, volume, and crew time must be used efficiently to optimize the delivery of in-flight medical care. Although commercial instruments can provide the blood and urine based measurements required for exploration missions, these commercial-off-the-shelf devices are prohibitive for deployment in the space environment. The objective of the ELA project is to close the technology gap of current minimally invasive laboratory capabilities and analytical measurements in a manner that the mission architecture constraints impose on exploration missions. Besides micro gravity and radiation tolerances, other principal issues that generally fail to meet NASA requirements include excessive mass, volume, power and consumables, and nominal reagent shelf-life. Though manned exploration missions will not occur for nearly a decade, NASA has already taken strides towards meeting the development of ELA medical diagnostics by developing mission requirements and concepts of operations that are coupled with strategic investments and partnerships towards meeting these challenges. This paper focuses on the remote environment, its challenges, biomedical diagnostics requirements and candidate technologies that may lead to successful blood-urine chemistry and biomolecular measurements in future space exploration missions.

Laboratory Analysis↗
NASA NTRS2000

The Instrument Synthesis for Analysis Laboratory at the Goddard Space Flight Center

The objectives of the Instrument Synthesis and Analysis laboratory (ISAL) are to: 1) Provide a rapid and sustainable instrument development environment with clear efficient processes and tools, re-usable models and skilled engineers. 2) Provide a capability for quick and efficient trade studies of instrument architectures and concepts. 3) Streamline and optimize instrument systems design for the entire life cycle, including cost and technology assessment. 4) Provide detailed multi-disciplinary modeling and analysis for phase C/D design validation and for operational investigations.

Wood, H. John↗
NASA NTRS2006

New Developments at NASA's Instrument Synthesis & Analysis Laboratory (ISAL)

This viewgraph document reviews the work of NASA's Instrument Synthesis and Analysis Laboratory (ISAL). The work of the ISAL has substantially reduced the time required to develop an instrument concept. The document reviews the design process in detail and planned interaction with the end user of the instrument.

Wood, H. John↗
NASA NTRS2007

Solving the AI Planning Plus Scheduling Problem Using Model Checking via Automatic Translation from the Abstract Plan Preparation Language (APPL) to the Symbolic Analysis Laboratory (SAL)

This paper describes a translator from a new planning language named the Abstract Plan Preparation Language (APPL) to the Symbolic Analysis Laboratory (SAL) model checker. This translator has been developed in support of the Spacecraft Autonomy for Vehicles and Habitats (SAVH) project sponsored by the Exploration Technology Development Program, which is seeking to mature autonomy technology for the vehicles and operations centers of Project Constellation.

Butler, Ricky W.↗
NASA NTRS2004

Instrument Synthesis and Analysis Laboratory

The topics addressed in this viewgraph presentation include information on 1) Historic instruments at Goddard; 2) Integrated Design Capability at Goddard; 3) The Instrument Synthesis and Analysis Laboratory (ISAL).

Wood, H. John↗
DOE OSTI2024

FRMAC Laboratory Analysis Manual Volume 1, Revision 0

This manual is written for personnel who respond to a nuclear/radiological incident and will be called upon to provide support to ensure that samples receive appropriate laboratory analyses. Overall, this manual provides general guidance and some specific diagrams and forms. However, it is understood that site- and incident-specific operational decisions and procedures may need to be modified at the time of the incident. This manual is intended to provide guidance for laboratory analysis personnel without limiting FRMAC’s ability to integrate the work with other partners and stakeholders. Some of the titles of management positions with the FRMAC have been changed in order to comply with the structure of the Incident Command System (ICS) under the National Incident Management System (NIMS).

61 RADIATION PROTECTION AND DOSIMETRY↗
DOE OSTI2023

Consequence Management Cobalt Magnet 2022 Laboratory Analysis: After Action Report

On May 16-20, 2022, federal mission partners (e.g., DOE Consequence Management, CDC, FDA, FBI, DHS) as well as integrated state, local, tribal, and territorial governments took part in Cobalt Magnet 22 (CM22), a large-scale, week-long radiological incident exercise in Austin, Texas, that linked several important national assets (National Search Program, Radiological Assistance Program, and Consequence Management [CM] personnel) into a single response effort. The exercise had nine (9) overarching Objectives and an additional 162 associated Critical Tasks for all the participating organizations. In total, 13 National Core Capabilities spanning 5 Mission Areas were represented in the final exercise. This exercise enabled a full range of capabilities to be fielded together and examine the operational connection between major assets, discover any resource shortages associated with conducting multiple mission areas simultaneously or in close succession, and identify any challenges related to leadership. This report summarizes nearly 100 successes and observations provided from players and controllers supporting the LA Division, Fly Away Laboratory (FAL) and Gamma Spectroscopist operations. The observations were categorized to align with the FRMAC programmatic functional areas to consider for future improvements: Logistics, CBRN Responder, Laboratory Analysis, Sampling and Monitoring, Health and Safety, Gamma Spectroscopist Operations, Fly Away Laboratory, and the FRMAC Interdivision Interoperability Group (FIIG).

54 ENVIRONMENTAL SCIENCES↗
NASA NTRS2012

In-Flight Laboratory Analysis

One‐year study objectives align with HRP requirements. HRP requirements include measurement panels for research and medical operations - These measurement panels are distinctly different. Instrument requirements are defined - Power, volume and mass not quite a critical limitation as for medical operations (deep space exploration missions). One‐year evaluation goals will lead HHC towards in‐flight laboratory analysis capability.

Baumann, David↗
DOE OSTI2017

Beryllium Laboratory Analysis--The Regulations May Drive the Science

Beryllium has many industry-specific applications, such as medical X-ray windows for diagnostic equipment, nuclear reactors, aerospace applications, precision instrumentation, and other consumer products for which lightness and rigidity is essential. According to the National Toxicology Program, beryllium oxide (BeO) is one of the most significant beryllium compounds in production. Although beryllium and its compounds have a wide array of beneficial uses, due to its unique properties it is not an ideal metal to be used in all situations. Exposure to beryllium is linked to beryllium sensitization and Chronic Beryllium Disease (CBD), which is incurable, debilitating, and potentially fatal. The International Agency for Research on Cancer classifies beryllium and beryllium compounds as “carcinogenic to humans” (Group I), and EPA classifies beryllium as a likely human carcinogen, the lung being the primary target organ. Laboratory analysis for beryllium samples has always presented a challenge to the analytical community. While most metals of interest to industrial hygienists have occupational exposure limits (OELs) in milligrams per cubic meter (mg/m 3 ), the beryllium OELs are in micrograms per cubic meter (μg/m3). Some regulatory agencies have recently published beryllium OELs so low that in some cases a laboratory limit of detection (LOD) in nanograms (ng) is required. For most substances, science drives the regulations, but for beryllium, regulations appear to be driving science to develop laboratory analytical methods that can adequately support the proposed OELs. (EPA has issued guidelines regarding ambient and community airborne beryllium exposure, but this article focuses on beryllium from an occupational exposure perspective.)

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗